VIGENCELL INC.VV

VIGENCELL INC.

3,260KRWD
+405+14.19%
At close at Mar 7, 09:00 GMT
KRW
No trades
See on Supercharts

308080 fundamentals

Key facts

Market capitalization‪62.80 B‬KRW
Basic EPS (TTM)−731.86KRW
Founded2013
CEOTae Gyu Kim
About

ViGenCell, Inc. engages in the research and development of pharmaceutical and immune cell therapy products. Its products pipeline includes ViTier, ViMedier, and ViRanger. The company was founded on February 1, 2013 and is headquartered in Seoul, South Korea.

Ownership
‪‪19.26 M‬‬
Free Float shares
‪‪12.80 M‬‬ (66.47%)
Closely held shares
‪‪6.46 M‬‬ (33.53%)
Free Float shares
‪‪12.80 M‬‬ (66.47%)
Closely held shares
‪‪6.46 M‬‬ (33.53%)
Capital structure
Market cap
‪‪62.80 B‬‬
Enterprise value
‪‪62.80 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪62.80 B‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
Valuation ratios
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪350.00‬
‪700.00‬
‪‪1.05 K‬‬
‪‪1.40 K‬‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−681,500.0%‬
‪−511,500.0%‬
‪−341,500.0%‬
‪−171,500.0%‬
‪−1,500.0%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−5.10 B‬‬
‪‪−3.40 B‬‬
‪‪−1.70 B‬‬
‪0.00‬
‪‪1.70 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−4.50 B‬‬
‪‪−3.00 B‬‬
‪‪−1.50 B‬‬
‪0.00‬
‪‪1.50 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−4.50 B‬‬
‪‪−3.00 B‬‬
‪‪−1.50 B‬‬
‪0.00‬
‪‪1.50 B‬‬

Dividends

Dividend yield, history and sustainability

308080 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−7.00 B‬‬
‪0.00‬
‪‪7.00 B‬‬
‪‪14.00 B‬‬
‪‪21.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
No data available
There's currently no assets and liabilities data to show.